Medindia

X

Renal Cell Carcinoma Drug Market Will More than Double Over the Next Decade, Rising from $625 Million in 2007 to Nearly $1.6 Billion in 2017

Wednesday, June 25, 2008 General News J E 4
Advertisement
WALTHAM, Mass., June 24 Decision Resources, one of theworld's leading research and advisory firms for pharmaceutical and healthcareissues, finds that the renal cell carcinoma drug market will more than doubleover the next 10 years, rising from $625 million in 2007 to nearly $1.6billion in 2017. Market growth will continue to be driven by the dominance ofthe multikinase inhibitors drug class, most notably Pfizer's Sutent.

According to the new Pharmacor report entitled Renal Cell Carcinoma,Sutent will maintain its position as the leading therapy for the disease andwill capture $841 million in sales in 2017 in the United States, France,Germany, Italy, Spain, United Kingdom and Japan. The report finds thatmultikinase inhibitors, which comprised 92 percent of the renal cell carcinomadrug market in 2007, will capture nearly three quarters of the market in 2017.

The report also finds that three emerging targeted therapies-GlaxoSmithKline's Armala, Pfizer's axitinib and Novartis's everolimus-willlaunch over the next decade and will achieve significant uptake in the second-line patient segment through 2017. Additionally, although there are notreatments that have, to date, shown efficacy in the adjuvant setting innonmetastatic renal cell carcinoma patients, the results of clinical trialsunderway in this patient segment could further drive market growth.

"The most notable trial currently underway, the Adjuvant Sorafenib orSunitinib in Unfavorable Renal Cell Carcinoma trial, is comparing the efficacyof Sutent versus Bayer Healthcare/Onyx's Nexavar versus placebo in extendingdisease-free survival in the adjuvant setting," said Ramya Kollipara, Ph.D.,analyst at Decision Resources. "If these drugs are approved for treatment inthe adjuvant setting, their use in this setting will be a major driver ofgrowth in the renal cell carcinoma market over the next decade."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Intersection of Financial and Regulatory Forces is...
S
MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,...